Company: NOTV
Filing Date: 2025-01-23
Form Type: DEF 14A
Source: 0001628280-25-002250
Chunk: 19

Company: Inotiv, Inc.
Filing Date: 2025-01-23
Form: DEF 14A
Chunk 19
---
     |           2021 |
| Terry Coelho                                                               |     |  63 |     | Director                            |     |           2023 |
| Class III Directors serving until the 2027 Annual Meeting of Shareholders: |     |     |     |                                     |     |                |
| Michael J. Harrington                                                      |     |  62 |     | Director                            |     |           2024 |
| David Landman                                                              |     |  69 |     | Director                            |     |           2023 |
| John E. Sagartz, DVM, Ph.D., DACVP                                         |     |  59 |     | Director and Chief Strategy Officer |     |           2018 |

Business Experience of Remaining Members of the Board

Nigel Brown, Ph.D. joined the Company’s Board as part of the Company’s acquisition of Envigo on November 5, 2021. Dr. Brown was initially elected to the Company’s Board in accordance with the terms of the Shareholders Agreement entered into as part of the acquisition of Envigo. Dr. Brown has been the Chief Executive Officer of Princeton Healthcare Advisory, LLC, a healthcare advisory firm, since 2015. Also, currently, Dr. Brown is an advisor to Rothschild & Co., Five Arrows Growth Capital, a financial advisory group. Dr. Brown has over 25 years of experience in the pharmaceutical, biotech, and contract research sectors, with particular expertise in pharmaceutical R&D. Trained as an analytical chemist, Dr. Brown has worked for a number of major pharmaceutical companies to develop, among other things, analytical methods in support of clinical drug metabolism and pharmacokinetic studies; LC/MS/MS technology for quantitative drug bioanalysis; and drug metabolism, pharmacokinetics, bioanalysis, genetic modeling, toxicology and manufacturing support. Dr. Brown also has extensive experience of deal-making in the pharmaceutical R&D sector, and has executed more than 25 deals spanning acquisition, divestiture, and strategic partnerships, with combined transaction value in excess of $10 billion. He served as Corporate Vice President of Business Development and Strategy for Covance, Inc. where he executed 19 transactions, including the strategic sale of Covance to LabCorp for $6.2 billion. Dr. Brown is a member of the board of directors of Universal Display Corporation. He holds an M.A. and D.Phil. from the University of Oxford, U.K., an M.B.A. from the Open University Business School,